Terms: = Uterine cancer AND CD274, PDL1, 29126, ENSG00000120217, PDCD1L1, PD-L1, MGC142296, PDCD1LG1, MGC142294, B7H1, Q9NZQ7, B7-H AND Treatment
227 results:
1. Comparison of programmed death-ligand 1 expression in adenocarcinoma and squamous cell carcinoma of the cervix in paraffin blocks of patients with cervical cancer.
Hosseini MS; Shafizadeh F; Bahremani MH; Farzaneh F; Ashrafganjoei T; Arab M; Talayeh M; Jafari F; Abdshah A
Cancer Rep (Hoboken); 2024 Apr; 7(4):e2057. PubMed ID: 38662366
[TBL] [Abstract] [Full Text] [Related]
2. Incorporation of anti-PD1 or anti pd-l1 agents to platinum-based chemotherapy for the primary treatment of advanced or recurrent endometrial cancer. A meta-analysis.
Bartoletti M; Montico M; Lorusso D; Mazzeo R; Oaknin A; Musacchio L; Scambia G; Puglisi F; Pignata S
Cancer Treat Rev; 2024 Apr; 125():102701. PubMed ID: 38422895
[TBL] [Abstract] [Full Text] [Related]
3. Mismatch repair gene
Zhou LZ; Xiao HQ; Chen J
Front Immunol; 2024; 15():1302797. PubMed ID: 38390329
[TBL] [Abstract] [Full Text] [Related]
4. Advanced detection of cervical cancer biomarkers using engineered filamentous phage nanofibers.
Zhou X; Wang Y; Bao M; Chu Y; Liu R; Chen Q; Lin Y
Appl Microbiol Biotechnol; 2024 Feb; 108(1):221. PubMed ID: 38372795
[TBL] [Abstract] [Full Text] [Related]
5. Evaluation of the anti-cancer efficacy of lipid nanoparticles containing siRNA against HPV16 E6/E7 combined with cisplatin in a xenograft model of cervical cancer.
Kang SW; Kang OJ; Lee JY; Kim H; Jung H; Kim H; Lee SW; Kim YM; Choi EK
PLoS One; 2024; 19(2):e0298815. PubMed ID: 38363779
[TBL] [Abstract] [Full Text] [Related]
6. Clinical benefit analysis of PD-1 inhibitors in patients with advanced, recurrent or metastatic cervical cancer: a meta-analysis and systematic review.
Wang YZ; Wang JS; Du J; Tang XL; Xiao JP
Front Immunol; 2024; 15():1305810. PubMed ID: 38327524
[TBL] [Abstract] [Full Text] [Related]
7. Immunotherapy for non-small cell lung cancer.
Kagamu H
Respir Investig; 2024 Mar; 62(2):307-312. PubMed ID: 38310751
[TBL] [Abstract] [Full Text] [Related]
8. Prevalence of pd-l1 in Cervical cancer Patients and the Potential for Combining an Immune Checkpoint Inhibitor With Lenvatinib.
Bräutigam K; Schmidt T; Baur M; Tauber N; Kontomanolis EN; Hemptenmacher F; Rody A; Köster F
Anticancer Res; 2024 Feb; 44(2):503-510. PubMed ID: 38307554
[TBL] [Abstract] [Full Text] [Related]
9. uterine Tumors Resembling Ovarian Sex Cord Tumors (UTROSCTs): A Scoping Review of 511 Cases, Including 2 New Cases.
Watrowski R; Palumbo M; Guerra S; Gallo A; Zizolfi B; Giampaolino P; Bifulco G; Di Spiezio Sardo A; De Angelis MC
Medicina (Kaunas); 2024 Jan; 60(1):. PubMed ID: 38276058
[TBL] [Abstract] [Full Text] [Related]
10. Comparative cost-effectiveness of first-line pembrolizumab plus chemotherapy vs. chemotherapy alone in persistent, recurrent, or metastatic cervical cancer.
Lin YT; Wang C; He XY; Yao QM; Chen J
Front Immunol; 2023; 14():1345942. PubMed ID: 38274823
[TBL] [Abstract] [Full Text] [Related]
11. Knowledge mapping of immunotherapy in cervical carcinoma: a bibliometric analysis (2000-2023).
Song L; Liang X; Zhu M; Su Q; Li F
Front Immunol; 2023; 14():1328103. PubMed ID: 38264659
[TBL] [Abstract] [Full Text] [Related]
12. The P286R mutation of DNA polymerase ε activates cancer-cell-intrinsic immunity and suppresses endometrial tumorigenesis via the cGAS-STING pathway.
Tang M; Yin S; Zeng H; Huang A; Huang Y; Hu Z; Shah AR; Zhang S; Li H; Chen G
Cell Death Dis; 2024 Jan; 15(1):69. PubMed ID: 38238314
[TBL] [Abstract] [Full Text] [Related]
13. Complete and early response to cemiplimab associated to severe immune toxicity in advanced cervical cancer: a case report.
Passarelli A; Pisano C; Coppola E; Ventriglia J; Cecere SC; Di Napoli M; Carideo L; Lastoria S; Pignata S
Front Immunol; 2023; 14():1303893. PubMed ID: 38193091
[TBL] [Abstract] [Full Text] [Related]
14. An Immune Gene Expression Risk Score for Distant Metastases after Radiotherapy for Cervical cancer.
Lukovic J; Pintilie M; Han K; Fyles AW; Bruce JP; Quevedo R; Pugh TJ; Fjeldbo CS; Lyng H; Milosevic MF
Clin Cancer Res; 2024 Mar; 30(6):1200-1207. PubMed ID: 38180733
[TBL] [Abstract] [Full Text] [Related]
15. Phase I Trial of First-line Bintrafusp Alfa in Patients with Locally Advanced or Persistent/Recurrent/Metastatic Cervical cancer.
Oaknin A; Ghamande SA; Kasamatsu Y; Gil-Martin M; Grau-Bejar JF; Garcia-Duran C; Sato M; Siddiqui A; Chaudhary SP; Vugmeyster Y; Hasegawa K
Clin Cancer Res; 2024 Mar; 30(5):975-983. PubMed ID: 38165683
[TBL] [Abstract] [Full Text] [Related]
16. Pharmacotherapy for the treatment of recurrent cervical cancer: an update of the literature.
D'Oria O; Bogani G; Cuccu I; D'Auge TG; Di Donato V; Caserta D; Giannini A
Expert Opin Pharmacother; 2024; 25(1):55-65. PubMed ID: 38159033
[TBL] [Abstract] [Full Text] [Related]
17. pd-l1 and PD-1 Expression in Early Stage uterine Endometrioid Carcinoma.
An HJ; Yang JW; Kim MH; Song DH
In Vivo; 2024; 38(1):246-252. PubMed ID: 38148043
[TBL] [Abstract] [Full Text] [Related]
18. Systematic assessment of tumor necrosis at baseline in cervical cancer - An independent factor associated with poor outcome.
Chouchane-Mlik O; Oniga A; Latouche A; Halladjian M; Kleine-Borgmann FB; Gérardy JJ; Mittelbronn M; Kamal M; Scholl SM
Hum Pathol; 2024 Jan; 143():62-70. PubMed ID: 38135059
[TBL] [Abstract] [Full Text] [Related]
19. Linking tumor immune infiltrate and systemic immune mediators to treatment response and prognosis in advanced cervical cancer.
Rocha Martins P; Luciano Pereira Morais K; de Lima Galdino NA; Jacauna A; Paula SOC; Magalhães WCS; Zuccherato LW; Campos LS; Salles PGO; Gollob KJ
Sci Rep; 2023 Dec; 13(1):22634. PubMed ID: 38114557
[TBL] [Abstract] [Full Text] [Related]
20. γδ T cell-mediated cytotoxicity against patient-derived healthy and cancer cervical organoids.
Dong J; Holthaus D; Peters C; Koster S; Ehsani M; Quevedo-Olmos A; Berger H; Zarobkiewicz M; Mangler M; Gurumurthy RK; Hedemann N; Chumduri C; Kabelitz D; Meyer TF
Front Immunol; 2023; 14():1281646. PubMed ID: 38090581
[TBL] [Abstract] [Full Text] [Related]
[Next]
